Treatment of coccidioidomycosis.

Current topics in medical mycology Pub Date : 1993-01-01
J R Graybill
{"title":"Treatment of coccidioidomycosis.","authors":"J R Graybill","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>This review has traced chemotherapy of coccidioidomycosis from its unsuccessful beginnings through the present time. Although in vitro susceptibilities give initial impressions of activity of many drugs, and although animal studies identify the diseases targeted for initial trials, ultimately it is the patient in whom the benefits and risks of a new agent must be weighed. For this reason, considerations have been limited to clinical studies, with no review of animal data or immunologic forms of therapy such as transfer factor. In this review, amphotericin B has been found to be the first active antifungal agent in coccidioidomycosis. Although responses clearly occurred, even in meningitis, the vagaries of disease and investigators prevented a really hard assessment of how many patients really were \"cured\" versus how many relapsed again and again. Responses were given in broad ranges and the term \"remission\" came to be considered a more accurate definition for this illness than \"cure.\" The azole antifungals, though fungistatic, gave us, for the first time, the ability to treat a patient indefinitely with an oral preparation; the advantages of this cannot be overstated. Although all of these drugs act by similar mechanisms, the differences in potency, pharmacokinetics and toxicities have brought fluconazole and itraconazole to the fore. Which of the two is superior (if either is) cannot be defined with the limited data available. The role of SCH39304 is, at present, unclear. Other agents such as nikkomycin and modified polyenes may enter a role in clinical evaluation of coccidioidomycosis, but for the next five years the drugs described in the preceding pages, or combinations, are likely to constitute the pharmaceutical arsenal against C. immitis. While we now have much more to offer the heirs of Domingo Escurra and Jose Furtado-Silveira than gentian violet and carbolic acid, we still have response rates of less than 75% for extrameningeal disease and we have not yet identified a drug that will guarantee a cure without later relapse. There is still a way to go.</p>","PeriodicalId":77092,"journal":{"name":"Current topics in medical mycology","volume":"5 ","pages":"151-79"},"PeriodicalIF":0.0000,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in medical mycology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This review has traced chemotherapy of coccidioidomycosis from its unsuccessful beginnings through the present time. Although in vitro susceptibilities give initial impressions of activity of many drugs, and although animal studies identify the diseases targeted for initial trials, ultimately it is the patient in whom the benefits and risks of a new agent must be weighed. For this reason, considerations have been limited to clinical studies, with no review of animal data or immunologic forms of therapy such as transfer factor. In this review, amphotericin B has been found to be the first active antifungal agent in coccidioidomycosis. Although responses clearly occurred, even in meningitis, the vagaries of disease and investigators prevented a really hard assessment of how many patients really were "cured" versus how many relapsed again and again. Responses were given in broad ranges and the term "remission" came to be considered a more accurate definition for this illness than "cure." The azole antifungals, though fungistatic, gave us, for the first time, the ability to treat a patient indefinitely with an oral preparation; the advantages of this cannot be overstated. Although all of these drugs act by similar mechanisms, the differences in potency, pharmacokinetics and toxicities have brought fluconazole and itraconazole to the fore. Which of the two is superior (if either is) cannot be defined with the limited data available. The role of SCH39304 is, at present, unclear. Other agents such as nikkomycin and modified polyenes may enter a role in clinical evaluation of coccidioidomycosis, but for the next five years the drugs described in the preceding pages, or combinations, are likely to constitute the pharmaceutical arsenal against C. immitis. While we now have much more to offer the heirs of Domingo Escurra and Jose Furtado-Silveira than gentian violet and carbolic acid, we still have response rates of less than 75% for extrameningeal disease and we have not yet identified a drug that will guarantee a cure without later relapse. There is still a way to go.

球虫病的治疗。
本文回顾了球孢子菌病的化疗从其不成功的开始到现在。尽管体外敏感性给了许多药物活性的初步印象,尽管动物研究确定了初始试验的目标疾病,但最终必须权衡新药物的益处和风险的是患者。出于这个原因,考虑仅限于临床研究,没有回顾动物数据或免疫形式的治疗,如转移因子。在这篇综述中,两性霉素B被发现是球虫真菌病的第一个有效的抗真菌药物。尽管有明显的反应,即使是脑膜炎,但疾病的变幻莫测和调查人员阻止了对有多少患者真正“治愈”,有多少患者反复复发的真正艰难评估。人们给出的反应范围很广,“缓解”一词被认为比“治愈”更准确地定义了这种疾病。唑类抗真菌药物虽然具有抑菌作用,但它第一次让我们能够用口服制剂无限期地治疗病人;这样做的好处怎么强调都不过分。虽然所有这些药物的作用机制相似,但在效价、药代动力学和毒性方面的差异使氟康唑和伊曲康唑脱颖而出。两者中哪一个更好(如果有的话)不能用有限的可用数据来定义。目前尚不清楚SCH39304的作用。其他药物如尼克霉素和改性多烯可能会在球虫真菌病的临床评估中发挥作用,但在未来五年内,前面几页中描述的药物或联合用药可能会构成抗球虫真菌病的药物库。虽然我们现在可以为多明戈·埃斯库拉和何塞·富尔塔多·西尔韦拉的继承人提供比龙胆紫和石碳酸更多的药物,但我们治疗外膜疾病的有效率仍然低于75%,而且我们还没有找到一种保证治愈而不会复发的药物。还有一段路要走。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信